14,100 reports of this reaction
2.8% of all GOLIMUMAB reports
#2 most reported adverse reaction
RHEUMATOID ARTHRITIS is the #2 most commonly reported adverse reaction for GOLIMUMAB, manufactured by Janssen Biotech, Inc.. There are 14,100 FDA adverse event reports linking GOLIMUMAB to RHEUMATOID ARTHRITIS. This represents approximately 2.8% of all 511,555 adverse event reports for this drug.
Patients taking GOLIMUMAB who experience rheumatoid arthritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHEUMATOID ARTHRITIS is a less commonly reported adverse event for GOLIMUMAB, but still significant enough to appear in the safety profile.
In addition to rheumatoid arthritis, the following adverse reactions have been reported for GOLIMUMAB:
The following drugs have also been linked to rheumatoid arthritis in FDA adverse event reports:
RHEUMATOID ARTHRITIS has been reported as an adverse event in 14,100 FDA reports for GOLIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHEUMATOID ARTHRITIS accounts for approximately 2.8% of all adverse event reports for GOLIMUMAB, making it one of the most commonly reported side effect.
If you experience rheumatoid arthritis while taking GOLIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.